Positive News SentimentPositive NewsNASDAQ:IMUX Immunic (IMUX) Stock Forecast, Price & News $1.48 +0.05 (+3.50%) (As of 12:13 PM ET) Add Compare Share Share Today's Range$1.45▼$1.5050-Day Range$1.35▼$2.4852-Week Range$1.11▼$11.76Volume62,596 shsAverage Volume1.02 million shsMarket Capitalization$66.01 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Immunic MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside237.8% Upside$5.00 Price TargetShort InterestBearish5.61% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.19) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.10 out of 5 starsMedical Sector562nd out of 972 stocksPharmaceutical Preparations Industry263rd out of 451 stocks 3.3 Analyst's Opinion Consensus RatingImmunic has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, Immunic has a forecasted upside of 237.8% from its current price of $1.48.Amount of Analyst CoverageImmunic has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.61% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Immunic has recently increased by 4.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMUX. Previous Next 3.8 News and Social Media Coverage News SentimentImmunic has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immunic this week, compared to 1 article on an average week.Search Interest5 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows4 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.50% of the stock of Immunic is held by insiders.Percentage Held by Institutions45.26% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($2.19) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Immunic (NASDAQ:IMUX) StockImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.Read More IMUX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUX Stock News HeadlinesSeptember 6, 2023 | finance.yahoo.comImmunic to Participate in Industry and Investor Conferences in SeptemberAugust 20, 2023 | proactiveinvestors.comImmunic completes enrollment in trial of vidofludimus calcium in patients with progressive MSSeptember 29, 2023 | PressReach (Ad)Uranium Prices Surge as Nuclear Energy Becomes KeyRenewed interest in uranium and rising prices have created a favorable environment for new projects.August 18, 2023 | proactiveinvestors.comImmunic CEO hails "great day" after completing IMU-838 phase 2 trial enrolmentAugust 4, 2023 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Immunic (IMUX)August 3, 2023 | proactiveinvestors.comImmunic CEO says Q2 results "couldn't be better"August 3, 2023 | finance.yahoo.comImmunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 1, 2023 | finance.yahoo.comImmunic to Participate in Investor and Scientific Conferences in AugustSeptember 29, 2023 | PressReach (Ad)Uranium Prices Surge as Nuclear Energy Becomes KeyRenewed interest in uranium and rising prices have created a favorable environment for new projects.July 28, 2023 | nasdaq.comWedbush Reiterates Immunic (IMUX) Outperform RecommendationJuly 27, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF), Pro Medicus Limited (OtherPMCUF) and Immunic (IMUX)July 27, 2023 | finance.yahoo.comImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate UpdateJuly 24, 2023 | finance.yahoo.comWith 50% stake, Immunic, Inc. (NASDAQ:IMUX) seems to have captured institutional investors' interestJuly 21, 2023 | proactiveinvestors.comImmunic Inc eyeing "big step" for multiple sclerosis patientsJune 29, 2023 | finance.yahoo.comImmunic to Participate in Scientific and Investor Conferences in JulyJune 27, 2023 | fool.comImmunic (NASDAQ: IMUX)June 27, 2023 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Immunic StockJune 21, 2023 | proactiveinvestors.comImmunic is developing a pipeline of oral therapies for chronic inflammatory and autoimmune diseasesMay 30, 2023 | proactiveinvestors.comImmunic ultimately hoping to "offer patients a new kind of treatment" for multiple sclerosisMay 30, 2023 | finance.yahoo.comImmunic to Participate in Scientific and Investor Conferences in JuneMay 17, 2023 | proactiveinvestors.comImmunic notes neuroprotective potential of vidofludimus calcium highlighted in preclinical dataMay 17, 2023 | proactiveinvestors.comImmunic says preclinical data for vidofludimus calcium is a milestone for its lead MS programMay 16, 2023 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Immunic (IMUX)May 12, 2023 | msn.comRecap: Immunic Q1 EarningsMay 12, 2023 | proactiveinvestors.comImmunic Inc set to bring relief with encouraging resultsMay 11, 2023 | washingtonpost.comImmunic: Q1 Earnings SnapshotMay 11, 2023 | finance.yahoo.comImmunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateSee More Headlines Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Company Calendar Last Earnings8/03/2023Today9/29/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees75Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+249.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-120,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-132.61% Return on Assets-113.76% Debt Debt-to-Equity RatioN/A Current Ratio4.74 Quick Ratio4.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book0.56Miscellaneous Outstanding Shares44,600,000Free Float42,588,000Market Cap$63.78 million OptionableNot Optionable Beta2.03 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Duane D. Nash J.D. (Age 52)M.B.A, M.B.A., M.D., Exec. Chairman Comp: $433.4kDr. Daniel Vitt Ph.D. (Age 55)CEO, Pres & Director Comp: $728.4kMr. Glenn Whaley CPA (Age 55)Chief Financial Officer Comp: $522.21kDr. Andreas Muehler M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $599.57kDr. Hella Kohlhof (Age 50)Chief Scientific Officer Jessica BreuHead of Investor Relations & CommunicationsMr. Inderpal Singh (Age 57)Gen. Counsel Mr. Patrick Walsh (Age 40)Chief Bus. Officer More ExecutivesKey CompetitorsAdageneNASDAQ:ADAGXilio TherapeuticsNASDAQ:XLOAdicet BioNASDAQ:ACETAEON BiopharmaNASDAQ:AEONEyenoviaNASDAQ:EYENView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 18,150 shares on 8/23/2023Ownership: 0.041%XTX Topco LtdBought 148,684 shares on 8/15/2023Ownership: 0.492%Citadel Advisors LLCSold 36,000 shares on 8/15/2023Ownership: 0.000%Schonfeld Strategic Advisors LLCBought 41,900 shares on 8/14/2023Ownership: 0.392%Two Sigma Securities LLCBought 14,346 shares on 8/14/2023Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions IMUX Stock - Frequently Asked Questions Should I buy or sell Immunic stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IMUX shares. View IMUX analyst ratings or view top-rated stocks. What is Immunic's stock price forecast for 2023? 2 brokers have issued twelve-month price targets for Immunic's shares. Their IMUX share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 249.7% from the stock's current price. View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts. How have IMUX shares performed in 2023? Immunic's stock was trading at $1.40 on January 1st, 2023. Since then, IMUX stock has increased by 2.1% and is now trading at $1.43. View the best growth stocks for 2023 here. When is Immunic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our IMUX earnings forecast. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) issued its earnings results on Thursday, August, 3rd. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.02. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and What is Immunic's stock symbol? Immunic trades on the NASDAQ under the ticker symbol "IMUX." How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Immunic's stock price today? One share of IMUX stock can currently be purchased for approximately $1.43. How much money does Immunic make? Immunic (NASDAQ:IMUX) has a market capitalization of $63.78 million. The company earns $-120,410,000.00 in net income (profit) each year or ($3.44) on an earnings per share basis. How can I contact Immunic? Immunic's mailing address is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. The official website for the company is www.immunic-therapeutics.com. The company can be reached via phone at (332) 255-9818, via email at jessica.breu@immunic.de, or via fax at 858-673-6843. This page (NASDAQ:IMUX) was last updated on 9/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.